FDA Accepts Allergan’s Supplemental New Drug Application (sNDA) for DALVANCE
Allergan plc has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Allergan’s supplemental New Drug Application (sNDA), for MRSA.
Pharmaceuticals, Biotechnology and Life Sciences
Allergan plc has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Allergan’s supplemental New Drug Application (sNDA), for MRSA.
National Institutes of Health (NIH) has launched a new phase of the Breast Cancer and the Environment Research Program (BCERP), focused on prevention.
U.S. Food & Drug Administration (FDA) has updated information on Drug Shortages.
Verona Pharma plc, a London-listed drug development company focused on medicines to treat respiratory diseases, has appointed new Non-Executive Directors of the Company
Novartis has announced a new analysis from the phase III FREEDOMS and FREEDOMS II trials reinforcing the long-term efficacy profile of Gilenya (fingolimod).
Sanofi and its subsidiary Genzyme announced positive new five-year investigational data from the extension study of Lemtrada (alemtuzumab) for patients with relapsing remitting multiple sclerosis (RRMS).
A federal judge in the U.S. District Court for the District of South Dakota yesterday granted the U.S. Food and…
Eli Lilly and Company and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, have announced financial commitment and continued scientific partnership to support the recently established Imaging Dementia – Evidence for Amyloid Scanning (IDEAS) Study.